The "Global Olaparib Market" size was valued at US$ 2.18 Billion in 2024 and is projected to reach US$ 3.86 Billion by 2030, at a CAGR of 10.0% during the forecast period 2024-2030.
"United States Olaparib Market" size was valued at US$ 987 Million in 2024 and is projected to reach US$ 1.72 Billion by 2030, at a CAGR of 9.7% during the forecast period 2024-2030.
Olaparib is an oral medication classified as a poly (ADP-ribose) polymerase (PARP) inhibitor, primarily used in the treatment of cancers with specific genetic mutations, such as BRCA1 or BRCA2. It is particularly effective in ovarian, breast, prostate, and pancreatic cancers that exhibit defects in DNA repair mechanisms. Here are key points about Olaparib:
-
Mechanism of Action:
- Olaparib works by inhibiting the PARP enzyme, which plays a critical role in DNA repair. By blocking PARP, cancer cells, particularly those with BRCA mutations, are unable to repair DNA damage and eventually die.
-
FDA Approval:
- Approved by the U.S. FDA for the treatment of advanced ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer in patients with BRCA mutations or other homologous recombination deficiencies (HRD).
-
Indications:
- Primarily used in patients with BRCA-mutated cancers. Indicated for maintenance therapy in ovarian cancer following a response to platinum-based chemotherapy and in advanced breast and prostate cancers.
-
Administration:
- Olaparib is taken orally, usually in tablet form, with the dose and duration determined based on the type of cancer and patient-specific factors.
-
Side Effects:
- Common side effects include fatigue, nausea, anemia, low white blood cell counts, and increased risk of infections. In rare cases, it can cause myelodysplastic syndrome or acute myeloid leukemia.
-
Targeted Therapy:
- Olaparib is part of the class of targeted therapies that focus on exploiting specific weaknesses in cancer cells, such as defective DNA repair, making it less toxic to normal cells compared to conventional chemotherapy.
-
Combination Therapy:
- Often used in combination with other treatments, such as chemotherapy or immunotherapy, to enhance its efficacy, especially in cancers resistant to single-agent therapies.
-
Clinical Trials and Research:
- Extensive ongoing research is being conducted to expand the use of Olaparib in other cancers and in combination with other drugs to target different pathways involved in cancer progression.
-
Companion Diagnostic:
- Genetic testing for BRCA mutations or other DNA repair defects is often required before initiating Olaparib therapy to identify patients most likely to benefit from the treatment.
Report Overview
This report provides a deep insight into the global Olaparib market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Olaparib Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Olaparib market in any manner.
Global Olaparib Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- AstraZeneca
- Everest Pharmaceuticals
By Type
By Application
- Ovarian Cancers
- Breast Cancers
- Prostate Cancers
- Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Olaparib Market
- Overview of the regional outlook of the Olaparib Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
| Report Attributes |
Report Details |
| Report Title |
Global Olaparib Market Research Report 2024(Status and Outlook) |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
95 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
Click for best price
